THE APEX TIMES
FDA advisory panel votes to expand list of substances pharmacies may compound, adding peptides despite agency scientists’ objections
The FDA’s Pharmacy Compounding Advisory Committee backed adding peptides to the agency’s permitted compounding list after a public meeting that included comments and presentations from FDA staff.
The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted to add peptides to the list of substances that compounding pharmacies may make, breaking with the position of agency scientists during a public meeting held this week, according to reporting by The Hill.
The vote came after the committee received public comment and heard presentations from FDA staffers describing the scientific issues raised for peptides, the report said. The agency scientists’ opposition centered on concerns about the basis for adding peptides, including questions about whether benefits have been demonstrated to support broad allowance for compounding.
Pharmacy compounding generally involves tailoring medications for individual patients, but it also operates within FDA rules that determine which ingredients are eligible for certain compounding activities. The permitted list is designed to provide a clearer regulatory pathway for compounding pharmacies, while still reflecting FDA’s assessment of the substances involved.
At the meeting, the committee considered the requested expansion of the permitted compounding category for peptides while weighing the concerns presented by FDA scientists, The Hill reported. The panel’s decision to move forward with adding peptides means the committee recommended that the ingredient be included among substances pharmacies can compound under the program’s framework.
FDA scientists had argued against adding the peptides, the report said, pointing to the agency’s views on the evidentiary record and the degree of demonstrated benefit. The panel nonetheless supported adding the substance, a step that can influence how FDA proceeds with regulatory updates tied to the advisory committee’s recommendations.
While the committee’s vote is advisory, the decision is part of a formal process in which FDA officials consider expert input and public comments as they determine how to handle compounding-related policy changes. The practical effect for pharmacies and patients depends on subsequent FDA actions that follow the committee’s recommendation.
Why It Matters
- Expanding the permitted compounding list can change what ingredients pharmacies are eligible to compound under FDA’s compounding framework, with downstream implications for availability.
- The panel’s vote highlights a recurring tension between agency scientific concerns and expert committee recommendations during FDA’s deliberative process.
- Because the advisory committee’s decision must still be followed by FDA implementation steps, the timeline for any policy change will depend on the agency’s next actions after the vote.
Key Facts
- On July 23, the FDA’s Pharmacy Compounding Advisory Committee voted to add peptides to the permitted list of substances that compounding pharmacies can make.
- The committee broke with the position of FDA agency scientists who had opposed adding peptides.
- The public meeting included public comments and presentations from FDA staffers raising scientific concerns related to peptides.
- The decision is tied to the FDA’s compounded drugs policy process and the advisory committee’s recommendations.